RFK Jr. Halts Alzheimer’s Screening Panel, Igniting Expert Outcry

Robert F. Kennedy Jr., the current U.S. Secretary of Health and Human Services, has effectively put the nation’s premier preventive‑care panel on ice. The U.S. Preventive Services Task Force – the independent group that usually meets three times a year to decide which screenings insurers must cover – has not been able to assemble since March 2025.

Why? In May the secretary dismissed the task force’s chair and let the terms of several members lapse without appointing replacements. The result is a skeletal board that may only reconvene in late August, and even then with up to eight fresh faces whose credentials are still under scrutiny.

Experts say the timing is troubling. John Ruiz, a clinical‑psychology professor at the University of Arizona who served on the panel, told The Guardian that the evidence for routine dementia screening “is not particularly strong.” He added that the panel itself has asked for more funding to bolster the data, but without a meeting those requests stay in limbo.

Kennedy has been vocal about what he calls “regulatory malpractice” – the failure to roll out early Alzheimer’s tests. Yet his own actions have been viewed by many as a parallel effort to reshape the task force in the same way he overhauled the Advisory Committee on Immunization Practices, firing its 17 members and installing vaccine skeptics.

“There’s the potential that they could reform the USPSTF in a way that is no longer evidence‑based or scientific,” warned Aaron Carroll, president of AcademyHealth, in an interview with Politico. He noted that the task force’s A‑to‑D ratings directly influence what insurers must cover without out‑of‑pocket costs, so a politicized shift could affect millions of wallets.

Alzheimer’s disease touches more than 7 million Americans, making it the most common form of dementia in the country. Early detection could become increasingly vital as new treatments appear to work best before severe cognitive decline sets in. Yet the medical community remains split on whether widespread screening is justified given the current evidence – “you get ten neurologists, you get ten approaches,” Ruiz observed.

Compounding the controversy, the NIH has stalled grant approvals for a dozen of the nation’s 35 Alzheimer’s Disease Research Centers, leaving researchers scrambling to retain staff and keep studies alive. Ann D. Cohen, co‑director of the University of Pittsburgh Alzheimer’s Center, bluntly told The Guardian that “science has been slowed down.”

Critics, including the Alzheimer’s Impact Movement, have accused Kennedy of spreading misinformation and demanded an apology to patients and families. In response, a HHS spokesperson reiterated the department’s commitment to advancing Alzheimer’s research, but offered no specifics on when the task force might finally meet again.

As the political tug‑of‑war over Alzheimer’s research and screening drags on, patients, caregivers, and clinicians are left waiting – hoping that evidence, not politics, will ultimately guide the next steps.